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Introduction 
PRRSV is the cause of significant reproductive and 
respiratory disease in swine worldwide. In Denmark, 
approximately 50 % of the herds are seropositive for 
PRRSV of either or both Type 1 or Type 2. In November 
2010, a pig herd in the Northern part of Denmark 
experienced an outbreak with Type 2 PRRSV where the 
clinical impact appeared to be much more severe than 
PRRSV was detected by real-time RT-PCR in all pigs 
inoculated (figure 1). The viremia peaked at DPI 7, and 
was significantly lower and of much shorter duration in 
the vaccinated group (group 4) compared to the 
unvaccinated animals (p= 0.04). Histopathology results 
are pending and will be presented. 
usually reported from Danish Type 2 PRRSV affected 
herds. Due to the clinical observations of reproductive 
failure (stillborn & mummified) in sows and high 
mortality in piglets, it was speculated that a new, more 
pathogenic PRRSV strain had evolved in Denmark. The 
aim of this study was: 1) to make a clinical 
characterization of the virus isolated from the herd by 
comparing the infection dynamics of the virus isolated 
from the herd with an older Danish Type 2 isolate (DK- 
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2010-10-13-1) by experimental infection in young pigs 
and 2) to assess the protective effect of a MLV Type 2 
vaccine  against  this  recent  Danish  Type  2  PRRSV 
isolate. 
 
Materials and Methods 
Samples from the PRRS clinical case collected in Nov 
2010 were obtained and the virus, designated DK-2010- 
10-13-1, was isolated in Marc-145 cells using general 
cell culture procedures and sequenced in full. Twenty- 
eight 4-week-old pigs from a commercial farm with 
health status according to the Danish Specific Pathogen 
Free (SPF) system were randomly divided into one 
control group N=4 (group 1) and three experimental 
groups (groups 2-4) (N=8). The groups were housed in 
separate sections at biosafety 3 facility. Pigs in group 4 
were vaccinated (2 ml i.m.) with Ingelvac® PRRS MLV 
vaccine (Boehringer Ingelheim Animal Health). Four 
weeks  later,  at  post  inoculation day  (DPI)  0,  pigs  in 
group 1 were sham- inoculated intranasally (i.n.) with 
Eagle’s MEM. Pigs in group 2 and group 3 were 
inoculated i.n. with DK-1997-19407B and DK-2010-10- 
13-1 isolates respectively. Pigs in group 4 were 
challenged with the DK-2010-10-13-1. The study was 
carried out in accordance with the Danish and EU 
regulations on the use of laboratory animals for research. 
Individual daily clinical scoring and individual rectal 
temps  were  recorded.  Blood  samples  were  collected 
from all pigs on DPI -28, 0, 3, 7, 10, 14, 21, 28, and 30 
for PRRS RT-PCR and serology. Samples were collected 
from lungs at necropsy for histopathology and virus 
quantification by RT-PCR. 
Results 
All pigs remained healthy throughout the experimental 
period. At necropsy, only minor lesions were revealed. 
Figure 1. Viral load in serum quantified by real-time 
RT-PCR 
 
Conclusions and Discussion 
PRRSV isolated from a herd experiencing overt clinical 
signs and significant mortalities, failed to induce 
comparable signs in this experimental set-up but if the 
reproductive infection model have been used the signs 
may have been more like the signs seen in the herd. Full 
genome  sequencing  of  the  isolate  revealed  that  the 
isolate was very similar to other Danish Type 2 isolates. 
Our data suggested that the severity of the disease in the 
field could be influenced by other factors than the virus 
and emphasize the need to aim further research for 
identifying virulence markers of PRRSV. In addition, the 
results demonstrated that vaccination with Ingelvac® 
PRRS MLV vaccine (Boehringer Ingelheim Animal 
Health) reduced viremia and viral excretion, thus being 
effective of limiting the impact of the DK-2010-10-13-1 
case virus and as such would be expected to be effective 
in  the  control  of  an  outbreak  with  this  and  related 
viruses.  These  findings  are  in  accordance  with  the 
finding  that  the  vaccine  was  used  effectively  in  the 
control of the infected herd. 
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